The study by Tee et al,1 which was first published online last November in the Archives, convincingly shows that the use of bisphosphonates in patients who are receiving long-term steroid therapy for bullous diseases can reduce steroid-induced osteoporosis. This is equally true for nonbullous diseases, as has been demonstrated in many placebo-controlled randomized trials reported in the medical literature. Numerous studies have also demonstrated poor bisphosphonate implementation in populations at risk for glucocorticoid-induced osteoporosis.
Albrecht J, Werth VP. Improving the Care of Our Patients Who Are Receiving Glucocorticoid TherapyComment on “Prevention of Glucocorticoid-Induced Osteoporosis in Immunobullous Diseases With Alendronate ”. Arch Dermatol. 2012;148(3):314-315. doi:10.1001/archdermatol.2011.2715